# US 2025/0017943 A1 · Pharmaceutical composition of diltiazem hydrochloride, preparation method therefor, and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017943 A1
- Document ID: US20250017943A1
- Status: Published application
- Kind: A1
- Application number: 18/901,715
- Filed: 2024-09-30
- Published: 2025-01-16
- Earliest claimed: 2022-07-22
- Assignees: Auson Pharmaceuticals Inc.
- Applicants: Auson Pharmaceuticals, Inc.
- Inventors: Peng Hou; Enxian Lu; Longlong Feng
- Web page: https://patentgrep.com/patent/US20250017943A1

## CPC

- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 9/0031: {Rectum, anus}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably a gel and comprises diltiazem hydrochloride and excipients including propylene glycol, benzoic acid, and a gel matrix, which comprises one or both of povidone and hydroxypropyl cellulose. Based on percentage by weight, the diltiazem hydrochloride accounts for 1%-5%, the gel matrix accounts for 5%-10%, with pH maintained at 3.0-4.5. A preparation method is provided accordingly, with simple and readily available raw materials and stable quality.

## Claims

### Claim 1

A pharmaceutical composition of diltiazem hydrochloride, which is in the form of a gel and comprises diltiazem hydrochloride and excipients, wherein the excipients comprise propylene glycol, one or both of benzoic acid and tartaric acid, a gel matrix, and optionally tocopherol, wherein the gel matrix comprises one or both of povidone and hydroxypropyl cellulose.

### Claim 2 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein, based on percentage by weight in the composition, the diltiazem hydrochloride accounts for 1%- 5%, the benzoic acid accounts for 0.1%- 5.0%, and the gel matrix accounts for 5%- 10%.

### Claim 3 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein based on percentage by weight, the diltiazem hydrochloride accounts for 1%- 4%, the benzoic acid accounts for 0.25%- 0.75%, and the gel matrix accounts for 7.0%- 9.0%.

### Claim 4 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein, based on percentage by weight in the composition, the diltiazem hydrochloride accounts for 1%- 5%, the tartaric acid accounts for 0.05% to 0.30%, and the gel matrix accounts for 5%- 10%.

### Claim 5 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein based on percentage by weight, the diltiazem hydrochloride accounts for 1%- 4%, the tartaric acid accounts for 0.10% to 0.20%, and the gel matrix accounts for 7.0%- 9.0%.

### Claim 6 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, which comprises both benzoic acid and tartaric acid.

### Claim 7 (depends on 6)

The pharmaceutical composition of diltiazem hydrochloride according to claim 6, further comprising tocopherol.

### Claim 8 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein the gel matrix comprises hydroxypropyl cellulose.

### Claim 9 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein the gel matrix comprises povidone.

### Claim 10 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein the gel matrix comprises povidone and hydroxypropyl cellulose.

### Claim 11 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein the diltiazem hydrochloride accounts for 2% or 4% by weight.

### Claim 12 (depends on 1)

The pharmaceutical composition of diltiazem hydrochloride according to claim 1, wherein, based on percentage by weight in the composition, the propylene glycol is greater than 80%.

### Claim 13 (depends on 12)

The pharmaceutical composition of diltiazem hydrochloride according to claim 12, further comprising tocopherol.

### Claim 14 (depends on 13)

The pharmaceutical composition of diltiazem hydrochloride according to claim 13, wherein, based on percentage by weight in the composition, the tocopherol accounts for up to 1% in the composition.

### Claim 15 (depends on 13)

The pharmaceutical composition of diltiazem hydrochloride according to claim 13, wherein, based on percentage by weight in the composition, the tocopherol accounts for 0.1% to 0.75% in the composition.

### Claim 16 (depends on 13)

The pharmaceutical composition of diltiazem hydrochloride according to claim 13, wherein the diltiazem hydrochloride accounts for 1%- 5%, the benzoic acid when present accounts for 0.1%- 5.0%, the tocopherol when present accounts for 0.25%-0.5%, and the gel matrix accounts for 5%- 10%.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein deacetyldiltiazem is no more than 3%.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, which is substantially from water.

### Claim 19 (depends on 1)

A method for preparing the pharmaceutical composition of claim 1, comprising the following steps: 1) mixing propylene glycol accounting for 35%- 70% of a prescribed or predetermined amount with a gel matrix, heating and stirring a resulting mixture for emulsification to obtain a matrix A; 2) mixing a prescribed or predetermined amount of one or both of benzoic acid and tartaric acid with the rest of the propylene glycol, and stirring a resulting mixture to obtain a solution B: 3) adding a prescribed or predetermined amount of diltiazem hydrochloride and optionally tocopherol to the solution B, stirring and heating a resulting mixture for dissolution to obtain a solution C; and 4) adding the solution C to the matrix A for overall mixing in a homogeneous and uniform manner, and cooling a resulting mixture to room temperature to obtain the pharmaceutical composition.

### Claim 20 (depends on 1)

A method of treating anal fissures and/or postoperative pain of anal fissures or hemorrhoids, comprising administration to a patient in need thereof the pharmaceutical composition of claim 1.
